ANIK logo

ANIK
Anika Therapeutics Inc.

641
Mkt Cap
$206.64M
Volume
113,126.00
52W High
$16.24
52W Low
$7.87
PE Ratio
-20.26
ANIK Fundamentals
Price
$15.37
Prev Close
$15.42
Open
$15.35
50D MA
$13.93
Beta
0.87
Avg. Volume
136,383.81
EPS (Annual)
-$0.7588
P/B
1.49
Rev/Employee
$480,080.85
$106.56
Loading...
Loading...
News
all
press releases
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?
Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Stock Crosses Above 200 Day Moving Average - Should You Sell?
Anika Therapeutics (NASDAQ:ANIK) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell...
MarketBeat·15d ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200 Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving Average - What's Next...
MarketBeat·23d ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving Average - Time to Sell?
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving Average - Here's Why...
MarketBeat·1mo ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen raised Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Trigran Investments Inc. Sells 415,296 Shares of Anika Therapeutics Inc. $ANIK
Trigran Investments Inc. lowered its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) by 20.4% in the third quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·2mo ago
News Placeholder
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company's strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference...
MarketBeat·2mo ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported $0.31 earnings per share for the quarter, beating analysts...
MarketBeat·2mo ago
News Placeholder
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock
Barrington Research boosted their target price on Anika Therapeutics from $16.00 to $17.00 and gave the company an "outperform" rating in a research note on Friday...
MarketBeat·2mo ago
<
1
2
...
>

Latest ANIK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.